LOAd703

DRUG2 trials

Sponsors

Lokon Pharma AB, Hoffmann-La Roche

Conditions

Biliary CarcinomaColorectal CancerOvarian CancerPancreatic Adenocarcinoma

Phase 1

Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer

CompletedNCT03225989

Lokon Pharma ABBiliary Carcinoma, Colorectal Cancer, Ovarian Cancer +1

Start: 2018-03-01End: 2023-08-22Updated: 2024-11-19

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

TerminatedNCT03555149

Hoffmann-La RocheColorectal Cancer

Start: 2018-09-27End: 2022-09-26Updated: 2023-11-07

Related Papers

Abstract CT169: Phase Ib/II open-label, randomized study of atezolizumab + regorafenib + AB928 or atezolizumab + regorafenib vs regorafenib for patients with microsatellite-stable, refractory metastatic colorectal cancer in MORPHEUS-CRC

Cancer Research2025-04-25

Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies

Cancer Research2023-04-141 citations

Abstract 6663: Immunostimulatory gene therapy targeting CD40/4-1BB in combination with chemotherapy induces an inflammatory gene profile in tumors from patients with advanced disease

Cancer Research2023-04-041 citations

Abstract 686: Immunostimulatory gene therapy with oncolytic viruses potentiates the effect of paclitaxel and cisplatin in ovarian cancer

Cancer Research2023-04-04

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer

Communications Medicine2022-07-1518 citations

Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus

Cancer Research2021-11-154 citations

Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2021-05-202 citations

Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.

Journal of Clinical Oncology2021-01-203 citations

259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC

Regular and Young Investigator Award Abstracts2020-11-012 citations

MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.

Journal of Clinical Oncology2019-01-2914 citations